Evidence map›Paper›PMID 27494892›Full record

ArticleOncotarget2016

Sirtuin 1 stimulates the proliferation and the expression of glycolysis genes in pancreatic neoplastic lesions.

Andreia V Pinho, Amanda Mawson, Anthony Gill, Mehreen Arshi, Max Warmerdam, Marc Giry-Laterriere, Nils Eling, Triyana Lie, Evelyne Kuster, Simone Camargo and 3 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
2.3field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 36 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 5 countries.

Andreia V PinhoCancer Division, The Garvan Institute of Medical Research, Sydney, Australia.
Amanda MawsonCancer Division, The Garvan Institute of Medical Research, Sydney, Australia.
Anthony GillCancer Division, The Garvan Institute of Medical Research, Sydney, Australia.
Mehreen ArshiCancer Division, The Garvan Institute of Medical Research, Sydney, Australia.
Max WarmerdamCancer Division, The Garvan Institute of Medical Research, Sydney, Australia.
Marc Giry-LaterriereCancer Division, The Garvan Institute of Medical Research, Sydney, Australia.
Nils ElingCancer Division, The Garvan Institute of Medical Research, Sydney, Australia.
Triyana LieCancer Division, The Garvan Institute of Medical Research, Sydney, Australia.
Evelyne KusterUniversity of Zürich, Zürich, Switzerland.
Simone CamargoUniversity of Zürich, Zürich, Switzerland.
Andrew V BiankinCancer Division, The Garvan Institute of Medical Research, Sydney, Australia.
Jianmin WuCancer Division, The Garvan Institute of Medical Research, Sydney, Australia.
Ilse RoomanCancer Division, The Garvan Institute of Medical Research, Sydney, Australia.
Garvan Institute of Medical Research · AUUniversity of Zurich · CHSt Vincent's Clinic · AUUniversity of Sydney · AU

Funding

Cancer Research UK 17263Cancer Research UK 22533
6 · The paper itself

Abstract

Metabolic reprogramming is a feature of neoplasia and tumor growth. Sirtuin 1 (SIRT1) is a lysine deacetylase of multiple targets including metabolic regulators such as p53. SIRT1 regulates metaplasia in the pancreas. Nevertheless, it is unclear if SIRT1 affects the development of neoplastic lesions and whether metabolic gene expression is altered.To assess neoplastic lesion development, mice with a pancreas-specific loss of Sirt1 (Pdx1-Cre;Sirt1-lox) were bred into a KrasG12D mutant background (KC) that predisposes to the development of pancreatic intra-epithelial neoplasia (PanIN) and ductal adenocarcinoma (PDAC). Similar grade PanIN lesions developed in KC and KC;Sirt1-lox mice but specifically early mucinous PanINs occupied 40% less area in the KC;Sirt1-lox line, attributed to reduced proliferation. This was accompanied by reduced expression of proteins in the glycolysis pathway, such as GLUT1 and GAPDH.The stimulatory effect of SIRT1 on proliferation and glycolysis gene expression was confirmed in a human PDAC cell line. In resected PDAC samples, higher proliferation and expression of glycolysis genes correlated with poor patient survival. SIRT1 expression per se was not prognostic but low expression of Cell Cycle and Apoptosis Regulator 2 (CCAR2), a reported SIRT1 inhibitor, corresponded to poor patient survival.These findings open perspectives for novel targeted therapies in pancreatic cancer.

Indexed as

Gene Expression Regulation, NeoplasticAnimalsCarcinoma in SituCarcinoma, Pancreatic DuctalCell Line, TumorCell ProliferationCell Transformation, NeoplasticDisease Models, AnimalGlucoseGlycolysisHumansMiceMice, TransgenicPancreatic NeoplasmsPrognosisSirtuin 1GlucoseSirtuin 1glycolysispancreatic ductal adenocarcinomaproliferationSirtuin 1tumorigenesis

Identifiers

PMID27494892
PMCPMC5342700
OpenAlexW2483760101

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.